Study Evaluating Pantoprazole in Peptic Ulcer Hemorrhage

Wyeth is now a wholly owned subsidiary of Pfizer149 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of intravenous pantoprazole in the prevention of rebleeding in patients with bleeding peptic ulcer disease after successful endoscopic hemostatic therapy.

Study Type

INTERVENTIONAL

Purpose

PREVENTION

Enrollment

149

Conditions

Peptic Ulcer Hemorrhage

Interventions

PantoprazoleDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must be men or non-pregnant women at least 18 years of age * Patients who present with a gastric or duodenal ulcer Exclusion Criteria: * Patients with ulcer appearance of clean base (non-oozing, non-spurting) or flat pigmented spot; adherent clots not removed by irrigation * Patients presenting with active bleeding and/or NBVV at 2 or more separate sites * Patients with any severe concomitant diseases, eg, end stage liver or renal disease, or unstable cardiovascular, pulmonary, renal, hepatic, or gastrointestinal diseases

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.